Status not kept up to date
Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer.
NCT04277858 · Nader Sadeghi · Updated 23 Oct 2023
- What is being tested
- Docetaxel
- For
- Oropharynx Cancer; Tonsil Cancer; Throat Cancer; Base of the Tongue Carcinoma
- Kind of study
- Tests a treatment or device on volunteers. Phase 2.
- Who can join
- Ages 18 years to 80 years. About 60 people. The full rules are on the registry page.
- Where
- Canada
- When
- Starts or started 14 Aug 2018, ends 30 Aug 2026. Registered 20 Feb 2020.
- Results
- None posted yet.
In the researchers' words
The objective of this trial is to study the efficacy of treatment of human papilloma virus (HPV) related oropharyngeal cancer with chemotherapy followed by Transoral Robotic Surgery (TORS) as definitive treatment. Current treatment of oropharyngeal cancer are chemo-radiotherapy. There is significant lifelong side effects associated with this approach related to tissue effects of radiotherapy. The side effects results in significant quality of life deterioration among the patients. Overall there is 20% failure rate with this treatment approach. The study hypothesis is that treatment with upfront (neoadjuvant) chemotherapy followed by transoral surgery and neck dissection is highly effective treatment allowing competitive cure rate compared to chemo-radiotherapy with less than 10% failure rate, while avoiding radiotherapy in majority of cases. It is also hypothesized that better functional and quality of life outcome maybe achieved with this approach.
Sites
- McGill University Health CentreMontreal, Quebec, Canada
